Stockscreener 앱 받기
14.73
8.85%
-1.43
시간 외 거래:
13.50
-1.23
-8.35%
전일 마감가:
$16.16
열려 있는:
$15.6
하루 거래량:
2.14M
Relative Volume:
0.93
시가총액:
$1.75B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-3.7577
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
-6.36%
1개월 성능:
+9.93%
6개월 성능:
+47.01%
1년 성능:
+37.02%
1일 변동 폭
$14.26
$16.04
1주일 범위
$14.26
$17.43
52주 변동 폭
$6.99
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.73 | 1.75B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) - Seeking Alpha
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Strengthens Team with Strategic Stock Grants to 5 Key New Hires - Stock Titan
(ARQT) Trading Report - news.stocktradersdaily.com
Arcutis stock holds buy rating, $19 target amid patent case - Investing.com Australia
Arcutis Biotherapeutics director sells $151,236 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics director sells $151,236 in stock - Investing.com Australia
Recent Insider Transactions at Arcutis Biotherapeutics - TradingView
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - MSN
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews - Benzinga
Arcutis stock holds buy rating, $19 target amid patent case By Investing.com - Investing.com UK
Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance
Arcutis stock rises following litigation stay By Investing.com - Investing.com Canada
Arcutis and Padagis agree to stay patent litigation By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus
Arcutis And Padagis Agree To Stay Patent Lawsuit - MarketScreener
Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha
Arcutis and Padagis agree to stay patent litigation - Investing.com India
Arcutis rises after halting patent dispute with Padagis - TradingView
Arcutis Agrees to Stay Patent Lawsuit Against Padagis - MarketScreener
Arcutis and Padagis Agree to Stay Patent Lawsuit - The Manila Times
Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan
Arcutis: An Agent of Patient-Centric Transformation - Technology Magazine
Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com
How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - MSN
Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - MSN
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance
Leading Immuno-Dermatology Player Arcutis Set for Major Investor Presentation at Needham Healthcare - Stock Titan
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Arcutis Biotherapeutics CEO sells $64,413 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics CEO sells $64,413 in stock - Investing.com
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
Arcutis throws to Odell Beckham Jr., the latest face of Zorvye foam - Medical Marketing and Media
Arcutis throws to Odell Beckham Jr., the latest face of Zoryve foam - MM+M Online
Arcutis Biotherapeutics shares jump - MSN
Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 By Investing.com - Investing.com South Africa
Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 - Investing.com India
What's Going On With Arcutis Biotherapeutics Stock Monday? - Benzinga
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age - Quantisnow
Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment - Marketscreener.com
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World
Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada
Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):